BioWorld

Feb. 20, 2007

Ziopharm Adds $31M For Clinical Oncology Pipeline

Ziopharm Oncology Inc. pulled in gross proceeds of $30.9 million in a private placement to advance ongoing clinical development of three lead cancer programs, two of which are expected enter pivotal testing this year. (BioWorld Today) Read More

Inspire Pads Late-Stage Pipeline With License To InSite's AzaSite

In Irritable Bowel Syndrome Pain, A General Mechanism

FDA Says No Strings Attached To PDUFA At Public Meeting

Holiday Notice

GPC's Satraplatin NDA Done, Drug Could Launch This Year

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...